VCEL News and Press, Vericel Corporation From 02/23/23

The following slide deck was published by Vericel Corporation in conjunction with their 2022 Q4 earnings call. For further details see: Vericel Corporation 2022 Q4 - Results - Earnings Call Presentation

Vericel press release ( NASDAQ: VCEL ): Q4 GAAP EPS of $0.12 beats by $0.08 . Revenue of $52.69M (+10.7% Y/Y) misses by $0.27M . MACI net revenue of $46.3 million and Epicel net revenue of $6.3 million 2023 Financial Guidance Total net revenue for...

Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million, with MACI Revenue of $132 Million Full-Year 2023 Total Revenue Guidance of $180 to $188 Million, with MACI Revenue of $152 to $156 Million Confe...

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 financial results on Thursday, February 23, 2023. Vericel’...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s note: “A Golden Ticket to Beat the Fed and Profit in ‘Hidden Bull Markets’ ” was previously published in August 2022 . It has since been updated to include the most relevant info...

Vericel ( NASDAQ: VCEL ) has reported prelim revenue of $164M-$165M for full-year 2022, in line with consensus estimate of $164.81M. MACI net revenue is expected to be ~$132M, at the high end of guidance range, with Q4 revenue growth of ~24% Y/Y. Burn Care net revenue is estim...

Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High End of Guidance Range, with Fourth Quarter Revenue Growth of Approximately 24% MACI Arthroscopic Commercial Launch Now Planned for 2024 CAMBRIDGE, Mass...

Summary Today, we take a deeper look at MediWound, an Israeli-based biopharma with some recent marketing application approvals. Those 'wins' has triggered a 50% rally in the stock, and the company continues to develop its pipeline as well. An investment analysis follows in the parag...

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41 st Annual J.P. Morgan Healthcare Conference...

Summary Various ongoing fundamental improvements signal significant upsides. The recent NexoBrid approval foretells leaping sales growth in the coming quarters. The lead franchise (Maci) is enjoying aggressive revenue growth that is far exceeding my expectations. ...